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EDITORIAL
Oral ibuprofen and the patent ductus arteriosus: a new approach 
to an old problem☆,☆☆
Ibuprofeno via oral e a persistência do canal arterial: uma nova abordagem 
para um problema antigo
Martin Kluckow
Royal North Shore Hospital, Sydney, Australia. Associate Professor, University of Sydney, Australia 
Patent ductus arteriosus (PDA) is present in up to 75% 
of infants born before 28 weeks gestation, and issues 
concerning PDA remain a popular topic in neonatology. 
The large range of articles addressing the assessment and 
treatment of PDA demonstrates the continuing uncertainty 
regarding the best way to manage an infant with this 
complication of prematurity. PDA is associated with many 
of the adverse outcomes of prematurity; however, there 
are conflicting results on the benefits of PDA closure from 
the many randomised and observational studies targeting 
PDA treatment. Consequently, there are ongoing questions 
as to when to treat, what to treat, and how to treat. 
Complicating factors, such as efficacy, dosage issues, 
risk of side effects, and the large variation in cost of 
potential treatments are becoming increasingly important, 
as neonatologists try to optimize available therapies. 
Neonatology has a track record of introducing medications 
before the pharmacokinetics in our population are properly 
understood. Enteral or intravenous indomethacin was 
the mainstay of PDA treatment for many years, ever 
since its use was first described in 1976.1,2 More recently, 
ibuprofen, initially as an intravenous infusion, has been 
utilized and found to be of similar efficacy as intravenous 
indomethacin.3 There are, however, indications that the 
appropriate dose to maintain therapeutic ibuprofen levels 
is not being achieved with intravenous dosing, resulting in 
increased treatment failure rates.4 Oral medication, which 
is simple to administer and effective, with minimal side 
effects, would be likely to change the balance in favour of 
treatment in many preterm infants. 
In this issue of the Journal, Yang et al.5 describe 
their experience with the use of oral ibuprofen versus 
intravenous indomethacin in a group of extremely low 
birth weight infants. In this retrospective cohort study, 
oral ibuprofen syrup (10 mg/kg initial dose, followed by 
two doses of 5 mg/kg at 24-hour intervals) was found to be 
as efficacious as intravenous indomethacin. The closure 
rate on initial treatment was 81.8% for oral ibuprofen 
versus 88.5% for intravenous indomethacin (p = 0.40). 
Importantly, there were no differences in side effects or 
complications between the two approaches. These were 
small infants, all under 1,000 g, and treated on average 
at 5 days of age. 
Other studies have confirmed the high closure rates 
and favourable safety profile of oral ibuprofen. Most 
recently, Erdeve et al.6 performed a randomised controlled 
trial of oral versus intravenous ibuprofen in 80 preterm 
infants, and found a higher initial closure rate with oral 
ibuprofen, though there was a higher re-opening rate in 
infants who received this treatment. Interestingly, there 
was also a reduction in the incidence of chronic lung 
disease in the orally treated group. Other studies have 
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reported favourable outcomes for infants treated with oral 
ibuprofen compared with either intravenous indomethacin 
or intravenous ibuprofen.7-12 One explanation for the 
improved efficacy of oral ibuprofen may lie within its 
pharmacokinetic profile. Oral ibuprofen administration 
results in more sustained therapeutic plasma levels. This 
was confirmed in a pharmacokinetic study by Barzilay et 
al.,13 who observed a high area under the curve (AUC) due 
to prolonged drug levels following oral dosage. This concept 
is further supported by studies of continuous indomethacin 
infusion, which also show better ductal closure when 
therapeutic levels are constantly maintained.14 
Neonatologists need a solution to the dilemma of 
which PDAs should be treated, and how to best achieve 
closure if indicated. Answers to the first question, are 
likely to come from more careful individual assessment 
of the physiological effects of the ductal shunt using 
techniques such as functional echocardiography,15 rather 
than performing large trials of treatment in infants 
with variable underlying physiology. Regarding the best 
management, the availability of an inexpensive, safe, and 
more efficacious medical treatment for PDA would be of 
major benefit to neonatologists internationally, particularly 
to those working in developing countries, where the 
prohibitive costs of new, intravenous medications make 
oral treatment an appealing option. Another relevant issue 
is the uncertainty of the supply of intravenous medications 
for PDA treatment, which has plagued neonatology over 
the past few years, as rival companies compete to provide 
a monopoly treatment. All of these factors amount to 
a potentially great benefit of the use of oral ibuprofen 
in the management of PDA. The evidence for the use of 
oral ibuprofen for initial PDA treatment, even in the most 
immature infants, is mounting, and the paper by Yang et 
al.5 adds further to this body of evidence. 
Conflicts of interest
The author has no conflicts of interest to declare. 
References
1. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick 
SE. Pharmacologic closure of patent ductus arteriosus in the 
premature infant. N Engl J Med. 1976;295:526-9.
2. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus 
arteriosus in premature infants by inhibition of prostaglandin 
synthesis. N Engl J Med. 1976;295:530-3.
3. Patel J, Marks KA, Roberts I, Azzopardi D, Edwards AD. Ibuprofen 
treatment of patent ductus arteriosus. Lancet. 1995;346:255.
4. Dani C, Vangi V, Bertini G, Pratesi S, Lori I, Favelli F, et al. High-
dose ibuprofen for patent ductus arteriosus in extremely 
preterm infants: a randomized controlled study. Clin Pharmacol 
Ther. 2012;91:590-6.
5.  Yang E, Song ES, Choi Y. Comparison of oral ibuprofen and 
intravenous indomethacin for the treatment of patent ductus 
arteriosus in extremely low birth weight infants. J Pediatr (Rio J). 
2013;89:33-9.
6.  Erdeve O, Yurttutan S, Altug N, Ozdemir R, Gokmen T, Dilmen 
U, et al. Oral versus intravenous ibuprofen for patent ductus 
arteriosus closure: a randomised controlled trial in extremely 
low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 
2012;97:F279-83.
7. Fakhraee SH, Badiee Z, Mojtahedzadeh S, Kazemian M, Kelishadi 
R. Comparison of oral ibuprofen and indomethacin therapy for 
patent ductus arteriosus in preterm infants. Zhongguo Dang 
Dai Er Ke Za Zhi. 2007;9:399-403.
8.  Aly H, Lotfy W, Badrawi N, Ghawas M, Abdel-Meguid IE, Hammad 
TA. Oral Ibuprofen and ductus arteriosus in premature infants: 
a randomized pilot study. Am J Perinatol. 2007;24:267-70.
9. Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral 
ibuprofen and intravenous indomethacin for closure of patent 
ductus arteriosus in preterm infants. J Med Assoc Thai. 2003;86: 
S563-9.
10. Supapannachart S, Limrungsikul A, Khowsathit P. Oral ibuprofen 
and indomethacin for treatment of patent ductus arteriosus in 
premature infants: a randomized trial at Ramathibodi Hospital. 
J Med Assoc Thai. 2002;85:S1252-8.
11. Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. 
Closure of patent ductus arteriosus with oral ibuprofen 
suspension in premature newborns: a pilot study. Pediatrics. 
2003;112:e354.
12.  Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. 
Efficacy and safety of oral versus intravenous ibuprofen in very 
low birth weight preterm infants with patent ductus arteriosus. 
J Pediatr. 2011;158:549-54.
13.  Barzilay B, Youngster I, Batash D, Keidar R, Baram S, Goldman 
M, et al. Pharmacokinetics of oral ibuprofen for patent ductus 
arteriosus closure in preterm infants. Arch Dis Child Fetal 
Neonatal Ed. 2012;97:F116-9.
14. Hammerman C, Shchors I, Jacobson S, Schimmel MS, Bromiker 
R, Kaplan M, et al. Ibuprofen versus continuous indomethacin 
in premature neonates with patent ductus arteriosus: is the 
difference in the mode of administration? Pediatr Res. 2008; 
64:291-7.
15. de Waal K, Kluckow M. Functional echocardiography; from 
physiology to treatment. Early Hum Dev. 2010;86:149-54.
02 Editorial 4-5.indd   5 4/3/13   16:46:33
